AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma
Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients who had received at least…
Myeloma
Researchers Identify 3 Genetic Alterations Associated with Higher Risk of Myeloma in African-Americans
Researchers have identified three genetic alterations associated with the known twofold to threefold risk of multiple myeloma among African-Americans. The study, “Differences…
Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients
Seattle Genetics is recruiting patients with relapsed or refractory multiple myeloma into a Phase 1 clinical trial to study the safety and tolerability of…
Darzalex Extends Time to Disease Progression, Death Among Newly Diagnosed Multiple Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who are not eligible for high-dose chemotherapy and stem cell transplant significantly benefit from the addition of Darzalex (daratumumab) to the standard…
Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests
Abnormally high production of an RNA editing enzyme called ADAR1 is associated with multiple myeloma progression and resistance to treatment, according to a study. The…
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’…
FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer
The U.S. Food and Drug Administration has allowed Fortis Therapeutics’ antibody-drug conjugate FOR46 to begin testing in a Phase 1 clinical trial as a…
FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb‘s Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, as a treatment…
Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows
Treatment with Darzalex (daratumumab) plus standard Revlimid (lenalidomide) and dexamethasone significantly delays the time to disease progression or death in newly diagnosed multiple myeloma…
Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research
Myeloma Crowd has launched an online tool called HealthTree, aimed at helping patients with multiple myeloma find the most appropriate therapies for their condition,…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML